December 2013 Br J Cardiol 2013;20:128–29 doi:10.5837/bjc.2013.32
Melvin D Lobo
Dr Melvin D Lobo (William Harvey Heart Centre, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London) The past three years has serendipitously seen the emergence of a novel class of device therapies for hypertension with renal sympathetic denervation (RSD) and baroreflex activation therapy currently leading the way. The intense interest in RSD is reflected in the fact that there are now more than 60 device manufacturers competing in this environment to produce technologies that cause renal nerve destruction through a variety of energy modalities based upon the fact that renal nerve
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits